Phase 1/2 × Dendritic Cell Sarcoma, Interdigitating × Sarcoma × Clear all
NCT03162536 2025-09-08

ARQ 531-101

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Active not recruiting
190 enrolled
NCT00002663 2023-02-13

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Atara Biotherapeutics

Phase 1/2 Completed
58 enrolled 18 charts
NCT01474681 2020-12-30

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

Novartis

Phase 1/2 Completed
27 enrolled 15 charts
NCT00006251 2020-01-21

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Completed
21 enrolled
NCT00078858 2020-01-18

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 1/2 Completed
37 enrolled
NCT00295880 2017-12-28

Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
12 enrolled 14 charts
NCT00003874 2011-11-29

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia

Fred Hutchinson Cancer Center

Phase 1/2 Completed
NCT00089037 2011-07-15

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Fred Hutchinson Cancer Center

Phase 1/2 Completed
NCT00010283 2010-04-02

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Fred Hutchinson Cancer Center

Phase 1/2 Completed